chemotherapy drug News
-
Siemens competition deadline approaching October 1
Less than two months remain for students to enter the 2010 Siemens Competition in Math, Science & Technology. A signature program of the Siemens Foundation, this annual competition for high school students awards college scholarships ranging from US$1,000 to US$100,000 for original research projects in both individual and team categories. Established in 1999, the Siemens Foundation has ...
-
2010 Siemens Competition registration opens today
Starting today, aspiring scientists and mathematicians nationwide can register for the 2010 Siemens Competition in Math, Science & Technology, the premiere original research competition for high school students in the United States. In just six months, submitted projects will be judged and the countdown to the national finals in Washington, D.C. will begin. Online registration and ...
-
Oncology Nurse Advisor Celebrates 10 Years
Oncology Nurse Advisor (ONA), a part of business media company Haymarket Media, Inc., is proud to celebrate their 10th anniversary this month. This milestone marks a decade of editorial excellence in the field of oncology nursing research and cancer care. Throughout the last decade ONA has evolved with the changes in nursing, starting as a print publication and transitioning over time to a ...
-
Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance. Drug therapy is one of the ...
-
Legionnaires’ Disease Outbreak Linked to Hospital Fountain
An outbreak of Legionnaires’ disease in Wisconsin has been linked to a decorative water wall in a hospital lobby, reports the Washington Post. A study published this week indicated that eight people contracted the life-threatening illness in 2010 after they walked by the water wall. None of the individuals were patients at the hospital at that time. Even with regular cleaning, says the ...
-
Legionnaires’ Cases Confirmed at Baltimore Nursing Home
Two cases of Legionnaires’ disease have been discovered at the Keswick Multicare Center on West 40th Street in Baltimore, MD. Their symptoms began in September, and health officials have now confirmed that the patients are indeed suffering from Legionnaires’, according to NBC affiliate WBAL-TV. Both patients are expected to recover. An investigation into the source of the outbreak ...
-
Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral. “We are very happy that the FDA has accepted our IND application to start our Phase ...
-
An Overview of Glioblastoma
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV ...
-
Preventing Wound Infections and Complications at Urgent Care
Cuts and lacerations are among the most common complaints that bring patients to urgent care clinics. Whether a wound originates from an accident with a sharp object, such as a kitchen knife or yard tool, or from a blunt force such as a fall, there may be a risk of infection. Urgent care providers are responsible for providing treatment that promotes healing and helps prevent wound infection. ...
-
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
By xCures
-
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Hengrui Therapeutics, Inc.
Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Hengrui Therapeutics, Inc. (HTI), a U.S. subsidiary of Chinese pharmaceutical company Jiangsu Hengrui Medicine Co., Ltd. (JHM), to develop a CDx that will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System. Once commercialized, the CDx will be used to identify non-small cell lung ...
-
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Pharmaceutical Assets Include Company’s Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN) Company’s Strategy is to Utilize the Phase 2 Study Grant Funds to Complete Preclinical Studies in CIPN and Ready the Company to Begin FDA Phase 1 Human Clinical Trials DOYLESTOWN, PA / ACCESSWIRE / September 28, 2021 / Neuropathix, Inc. ...
-
Current Treatment Options and Research for Glioblastoma
Glioblastoma originates in the brain and typically does not spread to other parts of the body. It is a particularly difficult cancer to treat because tumors often overlap with healthy brain tissue making full surgical removal usually impossible. Treatments such as chemotherapy and radiation may slow the disease’s progression, but there is currently no cure. Glioblastoma Multiforme is the ...
-
Neuropathix, Inc. Receives Patent Grant from India for its Novel Anti-Inflammatory Compounds
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the Company has been issued Indian Patent IN201617027528 specific to its global patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their ...
-
QXMedical Licenses Bioresorbable Embolic Technology from U of MN
QXMédical acquired the world-wide exclusive rights to the bioresorbable embolic technology developed by researchers and physicians at the University of Minnesota to fill a clinical need for resorbable and drug-loadable microspheres and hydrogels. Embolics are used by interventional radiologists and oncologists to occlude vessels for a variety of clinical indications. Current market leaders ...
By QXMedical
-
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. Lung cancer is the leading cause of cancer death accounting for almost one quarter of annual ...
-
FRONTBIO Inc Launches Preclinical Trials for its New Anticancer Drug
FRONTBIO a bio company that develops new pharmaceuticals announced on the 20th that it has developed a new anticancer drug that only kills cancer cells and will begin preclinical trials FRONTBIO confirmed the anticancer drug candidate FB320A3 signed a contract with the preclinical CRO Contract Research Organization and began the preclinical trials The phase 1 clinical trial will begin in 2022In ...
By Frontbio
-
Symberix Awarded Multiple SBIR Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs
Symberix, a leader in the discovery of drugs that selectively target the human microbiome, announced today that it has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). These grants will fund the research of new drugs that safely and selectively inhibit a bacterial enzyme responsible for a number of dose-limiting gastrointestinal (GI) ...
-
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere Technology for Cancer Drug Screening
Data suggests MOS platform recapitulates primary tumor tissue heterogeneity, including genomic and transcriptomic features, and microenvironment, comprising immune and stromal components MOS can be used in the evaluation of cancer drug response for chemotherapies and immunotherapies in the research setting Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology ...
By XILIS, Inc.
-
This year`s Medical Innovation Summit will highlight neurosciences innovation
Thousands of researchers, investors, entrepreneurs and those who are simply curious will descend upon the Cleveland Convocation Center October 26-28 for Cleveland Clinic Innovations Medical Innovation Summit. This year’s theme, The Neurosciences: Memory. Mood. Movement, will cover all aspects of the human brain and how it functions and malfunctions. “This is our marquee event,” ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you